Tag Archives: Dicerna Pharmaceuticals

← Older posts Newer posts →

Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO

Does the biotech bull market still have a pulse? MyoKardia, a three-year-old startup developing heart drugs, will soon try to find out. The San Francisco-based company filed papers with the SEC on Monday to go public and trade on the Nasdaq under the ticker symbol “MYOK.” MyoKardia would use the cash to advance its work […]

Posted in Boston blog main, Boston top stories, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO

East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s headlines. —This week a new type of cholesterol-lowering drug was in the spotlight, a class of injectable therapies that block the protein known as […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor

Back in April 2011, at a biotech conference in San Francisco, a panel convened to discuss how hard it was to build biotech companies that could push through long, costly clinical trials before a drug comes to market. One panelist hedged to say, well, at least the financial reticence had a silver lining: there was […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Big Events, Exits Raising Boston’s Innovation Profile at Year’s End

Boston’s stock as an innovation cluster is on the rise. At least in the eyes of the outside world. In addition to increased interest in the region’s technology and life sciences companies, there’s a critical mass of activity taking shape as we head into the new year. One notable effort: MIT Technology Review is organizing […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Big Events, Exits Raising Boston’s Innovation Profile at Year’s End

East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More

One of the year’s biggest cancer meetings took place this week in Barcelona, and many biotechs from the East Coast were angling for the spotlight. Some wowed investors, others, not so much. We’ve got the ups and downs and the rest of the week’s news and tidbits below: —Agios Pharmaceuticals (NASDAQ: AGIO) was one of […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More

John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief

John Maraganore opened up an envelope in 1994 that changed his life. Inside were the results of the pivotal study of an anticoagulant drug Maraganore had created in the lab. It was the star prospect for Maraganore’s employer, Biogen. If the drug, bivalirudin, worked, Biogen might have its first product—and Maraganore, the glory of designing […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

With $310M and Public Investors Aboard, Is a Juno IPO Next?

We won’t know for some time whether the cancer immunotherapies under development at high-powered Seattle startup Juno Therapeutics are the real deal. But there are plenty of investors willing to bet on them. Juno announced today that it has raised a $134 million Series B round from all of its “major” prior investors—the company didn’t […]

Posted in Boston blog main, National blog main, National top stories, New York blog main, New York top stories, Seattle, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With $310M and Public Investors Aboard, Is a Juno IPO Next?

Radius Health Yanks IPO, Cites Market Conditions

For the second time in two years, Radius Health is taking itself out of the IPO queue. The Cambridge, MA-based company has postponed its IPO, citing “poor market conditions,” according to IPO research firm Renaissance Capital. Radius had been looking to raise about $75 million and list on the Nasdaq under the ticker symbol “RDUS.” […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , | Comments Off on Radius Health Yanks IPO, Cites Market Conditions

Biotech IPO Slump Deepens as Alder Prices Below Range

As Alder Biopharmaceuticals can attest to today, the biotech IPO train has hit the skids. The Bothell, WA-based company has priced its IPO at $10 per share, well below its projected $13 to $15 per share range, according to IPO research firm Renaissance Capital. Alder upsized its offering to 8 million shares from 7.2 million […]

Posted in National blog main, New York blog main, Seattle, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech IPO Slump Deepens as Alder Prices Below Range

East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More

[Updated, 8:44 am ET] Local biotechs were out for cash this week. One company saw its share price triple in its first day on the Nasdaq. Three others lined up stock offerings. And one large healthcare conglomerate promised to open its data vault to a group of university researchers. Those stories and more below: —Watertown, […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More← Older posts Newer posts →